Inventor · disambiguated record
David Carroll
Also filed as: CARROLL DAVID · CARROLL DAVID M
48 granted patents·8 pending applications·1,204 citations·filing 2004–2024
99Inventor score
Top patents by PatentIndex Score
56 records- 0199US7452879B2Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compoundsRIGEL PHARMACEUTICALS INC·Filed 2006·Granted Nov 18, 2008·110 cites·13 claims
- 0299US7122542B2Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compoundsRIGEL PHARMACEUTICALS INC·Filed 2004·Granted Oct 17, 2006·218 cites·6 claims
- 0398US7560466B2Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compoundsRIGEL PHARMACEUTICALS INC·Filed 2006·Granted Jul 14, 2009·56 cites·11 claims
- 0498US7491732B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2006·Granted Feb 17, 2009·105 cites·6 claims
- 0597US10941134B2AMPK-activating heterocyclic compounds and methods for using the sameRIGEL PHARMACEUTICALS INC·Filed 2019·Granted Mar 9, 2021·18 cites·20 claims
- 0697US10377742B2AMPK-activating heterocyclic compounds and methods for using the sameRIGEL PHARMACEUTICALS INC·Filed 2017·Granted Aug 13, 2019·20 cites·21 claims
- 0797US7884111B22,4-pyrimidinediamine compounds and uses as anti-proliferative agentsRIGEL PHARMACEUTICALS INC·Filed 2006·Granted Feb 8, 2011·75 cites·12 claims
- 0897US7858633B2Cycloalkyl substituted pyrimidinediamine compounds and their usesRIGEL PHARMACEUTICALS INC·Filed 2006·Granted Dec 28, 2010·66 cites·5 claims
- 0997US7834024B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2008·Granted Nov 16, 2010·59 cites·6 claims
- 1096US10259826B2Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compoundsRIGEL PHARMACEUTICALS INC·Filed 2017·Granted Apr 16, 2019·6 cites·7 claims
- 1196US8415365B2Compositions and methods for inhibition of the JAK pathwayLI HUI·Filed 2008·Granted Apr 9, 2013·31 cites·20 claims
- 1296US8178671B2Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compoundsSINGH RAJINDER·Filed 2004·Granted May 15, 2012·31 cites·10 claims
- 1396US7947698B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2008·Granted May 24, 2011·55 cites·54 claims
- 1496US7915273B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2010·Granted Mar 29, 2011·33 cites·2 claims
- 1596US7754714B2Cycloalkyl substituted pyrimidinediamine compounds and their usesRIGEL PHARMACEUTICALS INC·Filed 2005·Granted Jul 13, 2010·39 cites·24 claims
- 1695US8809370B2AMPK-activating heterocyclic compounds and methods for using the sameRIGEL PHARMACEUTICALS INC·Filed 2013·Granted Aug 19, 2014·17 cites·7 claims
- 1795US8791136B2Substituted pyridine, pyridazine, pyrazine and pyrimidine compounds and methods for using the sameGOFF DANE·Filed 2011·Granted Jul 29, 2014·26 cites·27 claims
- 1895US8399472B2Compositions and methods for inhibition of the JAK pathwayLI HUI·Filed 2008·Granted Mar 19, 2013·26 cites·4 claims
- 1995US8193197B2Compositions and methods for inhibition of the JAK pathwayLI HUI·Filed 2007·Granted Jun 5, 2012·17 cites·38 claims
- 2094US9751893B2Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compoundsSINGH RAJINDER·Filed 2009·Granted Sep 5, 2017·8 cites·12 claims
- 2194US8987303B2AMPK-activating heterocyclic compounds and methods for using the sameRIGEL PHARMACEUTICALS INC·Filed 2013·Granted Mar 24, 2015·16 cites·24 claims
- 2294US8980921B2AMPK-activating heterocyclic compounds and methods for using the sameRIGEL PHARMACEUTICALS INC·Filed 2013·Granted Mar 17, 2015·16 cites·7 claims
- 2394US7868013B2Cycloalkyl substituted pyrimidinediamine compounds and their usesRIGEL PHARMACEUTICALS INC·Filed 2006·Granted Jan 11, 2011·25 cites·12 claims
- 2493US9266856B2AMPK—activating heterocyclic compounds and methods for using the sameRIGEL PHARMACEUTICALS INC·Filed 2014·Granted Feb 23, 2016·14 cites·30 claims
- 2593US8299087B2Compositions and methods for inhibition of the JAK pathwayLI HUI·Filed 2010·Granted Oct 30, 2012·11 cites·4 claims
- 2692US8809341B22,4-pyrimidinediamine compounds and uses as anti-proliferative agentsARGADE ANKUSH·Filed 2010·Granted Aug 19, 2014·9 cites·26 claims
- 2791US11198689B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2019·Granted Dec 14, 2021·2 cites·18 claims
- 2891US9598432B22,4-pyrimidinediamine compounds and uses as anti-proliferative agentsARGADE ANKUSH·Filed 2014·Granted Mar 21, 2017·7 cites·17 claims
- 2990US8304422B2Compositions and methods for inhibition of the JAK pathwayATUEGBU ANDY·Filed 2010·Granted Nov 6, 2012·26 cites·22 claims
- 3089US8815848B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2013·Granted Aug 26, 2014·8 cites·5 claims
- 3189US8410093B2Cycloalkyl substituted pyrimidinediamine compounds and their usesLI HUI·Filed 2010·Granted Apr 2, 2013·9 cites·20 claims
- 3288US9732073B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2015·Granted Aug 15, 2017·4 cites·17 claims
- 3387US10421752B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2017·Granted Sep 24, 2019·3 cites·14 claims
- 3487US9725419B2Cycloalkyl substituted pyrimidinediamine compounds and their usesRIGEL PHARMACEUTICALS INC·Filed 2013·Granted Aug 8, 2017·7 cites·3 claims
- 3587US7585883B2Substituted pyridines and their usesRIGEL PHARMACEUTICALS INC·Filed 2005·Granted Sep 8, 2009·10 cites·10 claims
- 3685US9481654B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2015·Granted Nov 1, 2016·5 cites·19 claims
- 3785US9248190B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2014·Granted Feb 2, 2016·4 cites·7 claims
- 3883US9409884B25- or 6-substituted benzofuran-2-carboxamide compounds and methods for using themRIGEL PHARMACEUTICALS INC·Filed 2013·Granted Aug 9, 2016·4 cites·17 claims
- 3981US9593082B2Compositions and methods for inhibition of the JAK pathwayARGADE ANKUSH·Filed 2008·Granted Mar 14, 2017·3 cites·17 claims
- 4081US2022073536A1Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compoundsRIGEL PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4180US11827628B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2021·Granted Nov 28, 2023·0 cites·19 claims
- 4279US8962643B2Compositions and methods for inhibition of the JAK pathwayLI HUI·Filed 2007·Granted Feb 24, 2015·3 cites·25 claims
- 4378US7482351B24-pyrimidineamine compounds and their uses as anti-proliferative agentsRIGEL PHARMACEUTICALS INC·Filed 2005·Granted Jan 27, 2009·2 cites·20 claims
- 4475US11230554B2Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compoundsRIGEL PHARMACEUTICALS INC·Filed 2019·Granted Jan 25, 2022·0 cites·7 claims
- 4570US12473926B1Impellers and manufacturing methods thereofMORRISON PRODUCTS INC·Filed 2024·Granted Nov 18, 2025·0 cites·20 claims
- 4670US11667611B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2019·Granted Jun 6, 2023·0 cites·19 claims
- 4768US9040543B2Compositions and methods for inhibition of the JAK pathwayRIGEL PHARMACEUTICALS INC·Filed 2014·Granted May 26, 2015·0 cites·17 claims
- 4866US2012253039A1Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine CompoundsSINGH RAJINDER·Filed 2012·Application pending·0 cites
- 4966US2005113398A12,4-pyrimidinediamine compounds and uses as anti-proliferative agentsFiled 2004·Application pending·0 cites
- 5062US2009093494A14-Pyrimidineamine Compounds And Uses As Anti-Proliferative AgentsRIGEL PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David Carroll files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →